Up to 67% of drug debuts fail to meet sales targets, a critical source of revenue to offset shortfalls, according to an EY report. Market introductions are often hindered by a reliance on legacy marketing strategies, and without new approaches, success rates aren’t likely to improve, Schur noted.

Here are three of the biggest drugs falling off the patent cliff this year and what companies can do to soften the blow.

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in revenue for Amgen’s biosimilar business.

Samsung Bioepis has released its Second Quarter 2025 Biosimilar Market Report, which provides the second quarter 2025 Average Sales Price and Wholesale Acquisition Cost of the commercially available biosimilars in the United States, as well as the price and market share trends since each biosimilar’s launch.

Among the most significant milestones was the launch of ustekinumab biosimilars following the loss of exclusivity for Stelara. This expansion has played a pivotal role in fostering market competition and encouraging more dynamic pricing strategies, the company said.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.

Emboldened by strong data for its oral IL-23 inhibitor icotrokinra in psoriasis, Johnson & Johnson has said it will see if it can outperform its big-selling injectable therapy Stelara in a head-to-head trial.

As Stelara biosimilars gradually make their way on to the U.S. market, Johnson & Johnson has accused one early adopter—Samsung Bioepis—of violating the settlement that paved the way for the launch of its biologic copycat earlier this week. The alleged breach of contract has prompted J&J to take the matter to court.

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States.

For 2025, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)—have again each excluded hundreds of drugs from their standard formularies. You can find our updated counting below.